Supriya Lifesciences got listed on the BSE at Rs.425 v/s IPO price of Rs.425, a huge premium of 55%. The stock came off this high listing and went down to Rs.308 and is now trading at Rs.401 levels.

This API manufacturer had seen a very good response to its IPO, subscribing 71.51 times with HNIs portion taking the lion’s share at 161.22 times, followed by retail investors at 56 times and QIBs at 31.83 times.

The company is one of India’s largest exporters of chlorpheniramine maleate, ketamine hydrochloride, salbutamol sulphate, commanding 30-60% export volume market share.

In our IPO Analysis, we had said, “company’s historic growth, high margins and debt-free status, post IPO, makes it attractive, at the offered price. Hence, we recommend applying in the IPO.”